Pendulum Therapeutics, a leading biotechnology company focused on microbiome science, has appointed Amy Errett to its Board of Directors. The company announced that Errett, Founder and CEO of Madison Reed, will join the board as Pendulum continues expanding its microbiome-based healthcare solutions.
The appointment comes as consumer interest in microbiome health continues to increase. Furthermore, awareness is growing around the microbiome’s impact beyond gut health. It now plays an important role in metabolic health, women’s health, and overall wellness.
Pendulum Therapeutics continues to develop clinically validated microbiome products. Additionally, the company aims to bring advanced microbiome science to wider audiences. Errett’s experience in building consumer brands and scaling purpose-driven businesses will support Pendulum’s next phase of growth.
Amy Errett Brings Consumer Brand Expertise to Pendulum Board
Amy Errett is a four-time entrepreneur, venture capitalist, and consumer brand executive. She founded Madison Reed with a vision to transform the hair color industry. The company focused on innovation, accessibility, and improved customer experiences.
Under Errett’s leadership, Madison Reed became one of the most recognized direct-to-consumer beauty brands in the United States. Moreover, the company built a strong omnichannel business model that serves millions of customers.
Before founding Madison Reed, Errett served as a General Partner at Maveron. The venture capital firm was co-founded by former Starbucks CEO Howard Schultz. Previously, she also served as Chief Asset Gathering Officer at E*TRADE. Currently, Errett works as a Venture Partner at True Ventures.
“We are thrilled to welcome Amy to our Board,” said Colleen Cutcliffe, PhD, Co-Founder and CEO of Pendulum Therapeutics. “Amy has an extraordinary track record of building beloved consumer brands that challenge the status quo and create meaningful impact. As we continue to bring groundbreaking microbiome science to more people, her experience scaling innovative businesses and connecting with consumers will be invaluable.”
“The most transformative companies are the ones that fundamentally change how people think about an important part of their lives,” said Amy Errett, Founder and CEO of Madison Reed, and Pendulum board member. “Pendulum is doing exactly that for human health. The company’s scientific rigor, groundbreaking work in the microbiome, and commitment to making cutting-edge innovation accessible to consumers are what drew me to the opportunity. I’m excited to join the Board and help Pendulum continue expanding its impact as awareness of the microbiome’s role in health continues to grow.”
“Amy’s decision to join Pendulum reflects the growing importance of the microbiome as a foundational pillar of health,” said Hugh Martin, Chairman and Chief Business Officer of Pendulum Therapeutics. “Her expertise in brand building, consumer engagement, and company growth will help accelerate our mission and expand awareness of the transformative potential of microbiome science.”
Pendulum Advances Microbiome Science and Healthcare Innovation
Beyond her business achievements, Errett has maintained a strong commitment to philanthropy and public service. She served on the board of GLIDE for more than 21 years. Additionally, she contributed to organizations including the University of Connecticut Foundation and Common Sense Media. She currently serves on the board of Wild Salmon Center.
Backed by more than a decade of research and development, Pendulum Therapeutics continues to build credibility in microbiome science. The company developed Pendulum Glucose Control, the first and only probiotic clinically proven to reduce A1C in people with Type 2 diabetes, as published by BMJ (2020).
Furthermore, Pendulum pioneered live Akkermansia muciniphila. This keystone strain helps strengthen the gut lining and supports metabolic balance. Today, Pendulum remains the #1 Gastroenterologist Recommended Brand of Akkermansia-based probiotics.
The company continues expanding microbiome science applications across metabolic health, digestive health, and whole-body wellness. Recently, Pendulum launched Gut Fuel, a doctor-formulated fiber mix-in powder designed to support the gut microbiome.
Gut Fuel combines resistant starches, diverse plant fibers, and polyphenol antioxidants. These ingredients help nourish beneficial gut bacteria. Moreover, its flavorless format allows consumers to add it easily to beverages, snacks, and meals without changing their eating habits.
Through continued innovation, Pendulum Therapeutics aims to make microbiome-based health solutions more accessible. The company’s latest board appointment strengthens its leadership as microbiome science gains wider recognition in the healthcare industry.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: PRNewswire.com
